Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-(2,5-dichloro-thiophen-3-yl)-pyrimidin-2-ylamine
- Development stage
- Unknown
- Lead developer
- University of Edinburgh
- Modality
- Small Molecules
01
Overview
A synthetic small molecule with the chemical formula C8H5Cl2N3S and a molecular weight of approximately 246.1 Da. It is an experimental compound identified as a potent inhibitor of cyclin-dependent kinase 2 (CDK2), a serine/threonine-protein kinase involved in cell cycle regulation. Structural studies have shown that this molecule binds to the ATP-binding site of CDK2 and can induce conformational changes in the activation loop of the enzyme. The compound was discovered through structure-based virtual screening and has been used as a lead for developing antiproliferative agents targeting CDKs[1][6][7]. There are no approved indications or clinical trials reported for this compound.
- Other names
- 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine4-(2,5-dichloro-3-thienyl)pyrimidin-2-amine4-(2,5-dichlorothiophen-3-yl)pyrimidin-2-amineCK1CK-1CK 1
02
Targets
CDK2 (Cyclin-dependent kinase 2)CDK1 (Cyclin-dependent kinase 1)CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on 4-(2,5-dichloro-thiophen-3-yl)-pyrimidin-2-ylamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-(2,5-dichloro-thiophen-3-yl)-pyrimidin-2-ylamine.